Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00437216 · ClinicalTrials.gov registry record
Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis
A clinical trial, sponsored by Galderma R&D.
- Completed
- Registry status
- 2,488
- Enrollment target
NCT00437216 is a clinical trial that has completed, run by Galderma R&D. The registered enrollment target is 2,488 participants.
The verdict
NCT00437216 has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- 2,488 participants
- Enrollment target
Study Summary
Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
Interventions
- DRUG Clobetasol Propionate, 0.05%
- DRUG Clobetasol propionate, 0.05% Spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,488 participants |
| Start Date | 2006-02 |
| Est. Completion | 2006-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00437216
The ClinicalTrials.gov registry entry for NCT00437216 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clobetasol Propionate, 0.05% is the first listed.
NCT00437216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00437216 about?
NCT00437216 is a clinical study titled "Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis". Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.
What is the current status of trial NCT00437216?
This trial is currently completed. The enrollment target is 2,488 participants. The study started on 2006-02. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00437216?
The interventions under investigation include: Clobetasol Propionate, 0.05% (DRUG), Clobetasol propionate, 0.05% Spray (DRUG).
Who is sponsoring clinical trial NCT00437216?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.